A promising step forward in melanoma treatment.
Published by NHS England on 14th April 2025
Melanoma UK were excited to hear about this landmark moment for people affected by advanced melanoma.
The SCOPE trial, developed by British biotech company Scancell, has officially launched as part of the NHS Cancer Vaccine Launch Pad (CVLP) – a national initiative expanding access to personalised cancer vaccine trials for people already diagnosed with cancer.
This new trial is designed to help reduce the risk of melanoma returning after treatment. It represents a major leap forward in cancer care, and we’re proud to support this NHS England initiative by helping to raise awareness and signpost patients to credible information.
💬 A message from us
At Melanoma UK, we hear regularly from people living with melanoma and families desperate for new options, and this news offers renewed hope.
💬 Interested in taking part?
If you’re currently being treated for melanoma, speak to your clinical team. They’ll be able to advise if you’re eligible for this vaccine trial.
More info on how the NHS is contacting patients to join can be found here:
Please share this update with anyone affected by melanoma. Awareness saves lives, and no one should face a diagnosis alone.
